A previous New Zealand case-control study of asthma deaths in the 5-45 year age group during 1981-3 found that prescription of fenoterol (by metered dose inhaler) was associated with an increased risk of death in patients with severe asthma. One major criticism of this study was that drug data for the cases and controls came from different sources. A new case-control design has been used to evaluate the same hypothesis, with a different set of asthma deaths, the same source for drug information being used for both cases and controls. This depended on identifying deaths from asthma during 1977-81 from national mortality records, and ascertaining which patients from those who died had been admitted to a major hospital for asthma during the 12 months before death. The study was confined to this subgroup, which accounted for about 20% of all asthma deaths in the areas served by a major hospital. For each of the eligible patients who died four age matched controls were selected from patients admitted to hospital for asthma during the year that the death occurred who had also had an admission for asthma in the previous 12 months. For the 58 cases and 227 control subjects information on prescribed drugs was collected from the hospital records relating to the previous admission. The odds ratio of asthma death in patients prescribed inhaled fenoterol was 1-99 (95% confidence interval 112-3-55, p = 0 02). As in the previous study, subgroups defined by markers of chronic asthma severity were also considered. The inhaled fenoterol odds ratio was 2-98 (95% CI 1-15-7 70, p = 0 02) in patients prescribed three or more categories of asthma drugs, 3-91 (95% CI 179-8 54, p < 0-01) in patients with a previous admission for asthma in the past 12 months, and 5 83 (95% CI 1-62-21-0, p = 0-01) in patients prescribed oral corticosteroids at the time of admission. In patients with the most severe asthma (defined by a previous admission for asthma during the past 12 months and prescribed oral corticosteroids at time of admission) the inhaled fenoterol odds ratio was 9-82 (95% CI 2-23-43 4, p < 0 01). These findings add further support to the hypothesis that inhaled fenoterol increases the risk of death in patients with severe asthma.
Abstract
A previous New Zealand case-control study of asthma deaths in the 5-45 year age group during 1981-3 found that prescription of fenoterol (by metered dose inhaler) was associated with an increased risk of death in patients with severe asthma. One major criticism of this study was that drug data for the cases and controls came from different sources. A new case-control design has been used to evaluate the same hypothesis, with a different set of asthma deaths, the same source for drug information being used for both cases and controls. This depended on identifying deaths from asthma during 1977-81 from national mortality records, and ascertaining which patients from those who died had been admitted to a major hospital for asthma during the 12 months before death. The study was confined to this subgroup, which accounted for about 20% of all asthma deaths in the areas served by a major hospital. For each of the eligible patients who died four age matched controls were selected from patients admitted to hospital for asthma during the year that the death occurred who had also had an admission for asthma in the previous 12 months. For the 58 cases and 227 control subjects information on prescribed drugs was collected from the hospital records relating to the previous admission. The odds ratio of asthma death in patients prescribed inhaled fenoterol was 1-99 (95% confidence interval 112-3-55, p = 0 02). As in the previous study, subgroups defined by markers of chronic asthma severity were also considered. The inhaled fenoterol odds ratio was 2-98 (95% CI 1-15-7 70, p = 0 02) in patients prescribed three or more categories of asthma drugs, 3- For both cases and controls information on prescribed drugs for self administration was extracted from records relating to the previous adtiission-that is, the admission within the 12 months before death for the cases and the corresponding prior admission for the control subjects. The number of hospital admissions for asthma during the 12 months prior to the admission under consideration (a marker of chronic asthma severity) was also ascertained from hospital notes.
We noted the prescribed asthma drugs at the time of admission as recorded in the admission notes and accident and emergency department notes and in the general practitioner's letter.
Prescribed medication at the time of discharge was recorded from the admitting officer's discharge notes, the discharge letter, and the discharge prescription. We could not obtain the data "blind," but the research workers were instructed to record all drug information from these sources. When more than one record was available from a particular source (for example, in the admission notes) the record with the most complete drug information was used.
The data forms were copied and all information that identified cases and controls was deleted. Two members of the study team (CB and JC) then made a blind assessment of the drugs at admission and discharge. In one case and six controls no information was available on the drugs at discharge, and they were assumed to be the same as the drugs at admission. Information from subsequent chest clinic and outpatient visits was available for some cases and controls, but this was relatively incomplete. Thus, unless otherwise specified, all findings refer to -drugs prescribed at discharge.
As in the previous study, the possibility of confounding or effect modification by severity was assessed by considering various subgroups defined by markers of chronic severity: (1) prescription of three of more categories of asthma drugs (oral or aerosolised beta agonists, nebulised beta agonists, theophyllines, sodium cromoglycate or inhaled corticosteroids, oral corticosteroids); (2) a hospital admission for asthma during the previous 12 months (that is, in the 12 months before the admission when the prescribed medication was recorded); (3) prescription of oral corticosteroids. When discharged most patients were taking several drugs, including oral corticosteroids. Thus we considered it most appropriate to define chronic severity in terms of the drugs being prescribed at the time of admission. As before, the main drug treatment of interest (fenoterol and other asthma drugs) related to the drugs prescribed at discharge.
DATA ANALYSIS
The Mantel-Haenszel procedure" was used to calculate odds ratios and test based confidence intervals (CI),'2 and Rothman's adaptation of this procedure'3 was used to perform a matched analysis. Logistic regression'4 was also used to calculate odds ratios adjusted for age, gender, ethnicity, and other potential confounders. On the basis of previous work,' we expected that about a quarter of the remaining 293 deaths would have occurred in people without any previous hospital admission. Thus we expected to find hospital records relating to about 220 deaths. The search of hospital records actually identified records for 214 patients who had died. Of these, 30 had died more than one hour after arrival at a hospital. As in the previous study, these were excluded because the focus of the study was on self administered asthma drugs (two patients who died within an hour of arrival were not excluded The odds ratio of asthma death was 1 93 in patients prescribed fenoterol by metered dose inhaled and 1-97 in patients prescribed fenoterol by nebuliser. In the previous study there were concerns about the completeness of the nebuliser data, since the drug information was from different sources for cases and controls. This concern did not apply in the current study, and so we considered it appropriate to pool the metered dose inhaler and nebuliser data in further analyses. The overall odds ratio for inhaled fenoterol was 1 99.
In contrast to the previous study, there were some differences in the inhaled fenoterol odds ratios between males (26 cases, 82 controls: odds ratio 2-77, 95% CI 1-13-6-79) and females (32 cases, 145 controls: odds ratio 1-53,95% CI 0-71-3 31), and between Europeans (36 cases, 3 91 in patients with a previous admission for asthma during the past 12 months, and 5-83 in patients prescribed oral corticosteroids at the time of admission. In patients who had both been admitted to hospital with asthma in the past 12 months (before the admission under consideration) and been prescribed oral corticosteroids at the time of admission the inhaled fenoterol odds ratio was 9-82.
As a check for possible bias we performed an analysis using only the drugs prescribed at admission, with no consideration of drugs at discharge. The inhaled fenoterol odds ratio was 1-72 overall, and 3 57, 3-10, 16-59, and 14-00 respectively in the four subgroups of chronic severity defined in table 3. In general, other antiasthma drugs did not seem to increase the risk of death disproportionately in patients with severe asthma (table  3) . In contrast to the previous study, however, increased odds ratios were observed for oral corticosteroids and for oral theophyllines in some subgroups. When subjects prescribed inhaled fenoterol were deleted from the analysis (to remove the interaction betwe-en the effects of fenoterol and oral corticosteroids), the odds ratios for oral corticosteroids at discharge were: 1-84 overall, and 2-93, 091, 0-26, and 0-78 in the four chronic severity subgroups defined in table 3. When the analysis was adjusted (by the Mantel-Haenszel method") for oral corticosteroids at discharge the inh'aled fenoterol odds ratios were 1 85 overall, and 2 61, 3 76, 5 89, and 9 31 in the four chronic severity subgroups.
Discussion
There are now three New Zealand case-control studies, each using different sources of data, indicating that inhaled fenoterol-increases the risk of death in patients with severe-asthma. The fenoterol odds ratio estimate of 1 99 in the current study for patients with a hospital admission for asthma during the previous 12 months is consistent with the estimates of 2 16 in our previous national case-control study' and 3 00 in the small Auckland case-control study.' '5 The patterns of findings in the patients with the most severe asthma are also similar in the three studies.
The larger inhaled fenoterol odds ratios in males and in non-Europeans in the current study are inconsistent with the results of our previous study. Further investigation would be warranted, particularly as the epidemic appears to have been more severe in non-Europeans.'6 A more consistent finding is that the increased risk of death associated with fenoterol was particularly strong in those aged less than 20 years. The reason for this remains to be clarified, though it could be due to either a greater tendency to overuse (or use inappropriately) inhaled beta agonists in young people or a reduced response to cardiac beta, stimulation with increasing age. '7 The study design used here has some important differences from that of our previous casecontrol study.' The current study was restricted to cases and controls with a previous hospital admission for asthma during the 12 months before death (for the cases) ' The most important feature of the current study is that the information on prescribed drugs was obtained from hospital records in an identical manner for cases and controls, and was assessed blind. The initial recording of prescribed medication from hospital records could not be performed blind, but the recording process was very comprehensive and all relevant information was extracted from the case notes.
We must emphasise that this study examined prescribed medication at the time of a hospital admission on average three to four months before death or the admission of interest, and that no information on actual drug use was available. Ifour hypothesis concerns a mechanism depending on long term use, then the regular prescribed medication is the factor of interest. For other possible mechanisms the self administered medication actually used in the final attack would be relevant. Given that this is not available, the regular prescribed medication is an acceptable surrogate, as asthmatic patients are very likely to use their prescribed medication in an acute attack. There is no reason to believe that the small proportion of patients who failed to take medication in an acute attack would differ substantially according to the beta agonist that was prescribed. Thus the major concern is that the use of this surrogate measure could produce a bias towards 1 0 in the observed odds ratio.'8 Despite this concern the regular prescribed medication may be the most valid available measure, because changes in drug treatment at the time of the final attack could lead to bias. These issues are readily understood in the context of a clinical trial in which data are analysed according to the "intention to treat" principle.
As in our previous case-control study, an important methodological issue is the potential for confounding by severity. A previous New Zealand study '5 has showed many similarities between patients admitted to hospital with asthma and patients who die of asthma. Major differences in average severity between the case and control groups in this study thus appear unlikely, particularly as both groups had a hospital admission for asthma followed by another attack (resulting in hospital admission or death) during the subsequent 12 months. In addition, cases and controls were very similar with regard to various markers of chronic asthma severity. Despite the problems of obtaining a "definitive" marker of chronic severity, these markers do have the merit that they are based on information that would have been available to the physician at the time the beta agonist was prescribed. Information not available to the physician at that time is not relevant to the issue of confounding by severity. If the overall increased fenoterol odds ratio had been due to confounding by chronic severity, this would be expected to decrease as the analysis was increasingly restricted to subjects with more severe chronic asthma. Instead, the inhaled fenoterol odds ratio increased substantially. This indicates that our findings are not due to confounding by chronic asthma severity.
In contrast to the previous study, increased odds ratios were observed for oral corticosteroids and for oral theophyllines in some subgroups. Both of these categories of drugs were prescribed on discharge to most patients with severe asthma, and the confidence limits for the odds ratios are accordingly very wide. The overall odds ratio for oral theophyllines, however, was only 1I 0, and the increased odds ratios in the most severe subgroups could have been due to chance.
The findings for oral corticosteroids on discharge are puzzling, and are inconsistent with those in our previous study.' They were not of strong a priori interest, in contrast with the fenoterol findings. They do, however, raise the possibility of differences inl acute severity (but not chronic severity) betvseen cases and controls, a hypothesis that is consistent with the tendency for the differences to diminish in the most severe subgroups (table 3). But there was little evidence of differences in oral corticosteroid treatment at discharge between cases and controls when the fenoterol effect was removed, and adjustment for oral corticosteroids at discharge resulted in only minor changes to the estimates for the fenoterol effect. Furthermore, there was little evidence of differences for other markers of acute severity or for markers of chronic severity (including oral corticosteroids on admission), which is of greater relevance.'9 Thus the findings regarding inhaled fenoterol seem unlikely to be due to confounding by severity. Instead, the data indicate that inhaled fenoterol increases the risk of death in patients with severe asthma.
Our previots case-control study has been criticised for using markers of chronic asthma severity rather than markers of the severity of the final attack.202' As noted above, however, both studies have examined prescribed medication. When we are considering confounding therefore attention should be focused on risk factors that may be associated with prescription of fenoterol.'9 The severity of the final attack is irrelevant in this context, as this usually occurred several months after prescribing occurred. In fact, for all of the hypothesised mechanisms the severity or the life threatening nature of the final attack could be a result of using fenoterol. Thus controlling for the severity of the final attack is at best irrelevant, and may lead to serious bias. Once again, these issues are most readily understood in the context of a clinical trial analysed according to the "intention to treat" principle.
In summary, the findings of the current study are consistent with the hypothesis that inhaled fenoterol increases the risk of death in patients with severe asthma. Our previous study produced similar findings, but the possibility of information bias could not be excluded owing to the collection of drug information from different sources for cases and controls. This potential bias is avoided by the study design used here. No single case-control study may be regarded as conclusive, because not all sources of bias can be definitely excluded. The findings presented here, however, add support to the hypothesis that the unsupervised self administration of fenoterol by inhalation in patients with severe asthma increases the risk of death.
